RSCM
GPCR icon

Rock Springs Capital Management’s Structure Therapeutics GPCR Stock Holding History

Rock Springs Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-65,600
Closed -$2.58M – 113
2024
Q2 		$2.58M Buy
+65,600
New +$2.69M 0.08% 99

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Rock Springs Capital Management's GPCR Position: Q1 2026 in Review

Rock Springs Capital Management reduced its Structure Therapeutics (GPCR) stake by 14% in Q1 2026, selling an estimated $7.39M and leaving 640,217 shares worth $30.9M. The position accounts for 1.82% of the portfolio, ranked #18.

Rock Springs Capital Management first reported a position in GPCR in Q4 2023 and has held it in 10 quarters since. The position peaked at $52M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Rock Springs Capital Management held 640,217 shares of Structure Therapeutics worth $30.9M as of Q1 2026.
  • Rock Springs Capital Management sold 108,019 Structure Therapeutics shares in Q1 2026, an estimated $7.39M.
  • Structure Therapeutics made up 1.82% of Rock Springs Capital Management's portfolio in Q1 2026, its #18 holding.
  • Rock Springs Capital Management first reported a position in Structure Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Rock Springs Capital Management's Structure Therapeutics position peaked at $52M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.